Leerink Partners analyst Joseph Schwartz weighed in on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following today's FDA briefing docs, noting they ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

BioMarin (BMRN) PT Cut to $100 at Baird; Sees Drisapersen Approval 'Near-Zero'November 23, 2015 7:16 AM BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCTNovember 20, 2015 12:33 PM BioMarin (BMRN) Has Good Risk/Reward Despite Cautious FDA Briefing Documents for Drisapersen, Says RBCNovember 20, 2015 10:12 AM BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)November 20, 2015 9:50 AM Data does not support nod for BioMarin's DMD drug: FDA staffNovember 20, 2015 9:12 AM Sarepta Therapeutics (SRPT) Surges 25% Following BioMarin (BMRN) Briefing DocsNovember 20, 2015 8:36 AM BioMarin Pharma (BMRN) Announces Consistent Drisapersen Efficacy Evidence Demonstrated Across Three StudiesNovember 20, 2015 8:12 AM BioMarin Pharma (BMRN) Affirms Posting of Drisapersen NDA Briefing DocsNovember 20, 2015 8:11 AM BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa™ (drisapersen) in Comparable Patients Across Three Randomized StudiesNovember 20, 2015 8:11 AM FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa™ (drisapersen) for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 SkippingNovember 20, 2015 8:10 AM FDA Posts Breifing Docs for BioMarin Pharma's (BMRN) DrisapersenNovember 20, 2015 7:59 AM BioMarin Pharma (BMRN) FDA briefing docs releasedNovember 20, 2015 7:59 AM Baird Expects FDA Rejection for Drisapersen and Eteplirsen (BMRN) (SRPT)November 19, 2015 8:18 AM